CymaBay Therapeutics, Inc. CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc.

CBAY

Rang in aandelen #5847
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical... CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
Aandeelprijs
$32.48
Laatst gesynchroniseerd: 2024-03-25
Marktkapitalisatie
$2.24B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-0.01%
Land
US
Handel CymaBay Therapeutics, Inc. (CBAY)

Categorie

Healthcare
Dividendrendementgeschiedenis voor CymaBay Therapeutics, Inc. (CBAY)
Het dividendrendement (TTM) van CymaBay Therapeutics, Inc. (aandelsymbool: CBAY) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van CymaBay Therapeutics, Inc. (CBAY) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.17%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL